Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| IBSRELA's performance to-date and as Susan shared earlier, the continued insight from our in-field experience has strengthened our confidence in the potential for this product |
| Medical education for patients and HCPs, as well as data dissemination via abstract presentations and publications, continue to provide valuable insight and enhance the science around our products and more generally within these therapeutic areas, which brings me to one of the data-gathering programs that I'm extremely excited about |
| The foundational elements of the Ardelyx commercial approach are all working together and we are incredibly pleased with the performance thus far |
| And then overall, they're telling us that the patients are responding favorably and satisfied and they're seeing reductions in phosphorus levels |
| IBSRELA and XPHOZAH are demonstrating favorable market response with high healthcare practitioner interest and continuously expanding adoption |
| We're seeing patients reducing the binder dose and adding XPHOZAH and also having a favorable experience |
| These are all positive launch indicators that we believe will result in continued, consistent and persistent uptake |
| The growth momentum we are seeing for both IBSRELA and XPHOZAH is exciting |
| So the feedback that we're getting from the physicians treating patients with IBSRELA is really highly favorable in terms of the patient response to therapy and satisfaction with therapy |
| So we're quite confident that there's a really strong opportunity within the labeled claim |
| IBSRELA's mechanism of action, solid clinical data, and a growing user base of positive experience is resonating, driving expanding consideration and adoption by more and more healthcare practitioners |
| What we see is consistent and persistent growth driven by the market need, favorable market access and key demand creation fundamentals that are delivering on the mission of Ardelyx to bring a novel mechanism therapy to patients who, despite treatment with available therapies are in great need of a new option |
| Finally, we are also seeing strong market interest and responsiveness to our in-market messaging centered on the novel phosphate blocking mechanism and clinical profile of XPHOZAH |
| Our strong performance in 2023 was driven by consistent uptake for IBSRELA across each of our key measures, including new writers and repeat writers, as well as new and refilled prescriptions |
| In addition to a positive therapeutic response and patient experience reported by physicians, we are rapidly establishing a favorable access landscape for XPHOZAH |
| I am very excited about what XPHOZAH may be able to do for our patients and capturing data in a real-world setting will not only supplement the insights we've gained in our clinical trials, but more importantly will further expand our understanding and enhance our ability to support the patients and the physician communities who are constantly striving to manage serum phosphorous in the setting of end-stage kidney disease |
| And with our successful track record of discovery, development, and regulatory approvals, we also have the opportunity to develop earlier stage assets ourselves |
| So both from an access and affordability standpoint, our patient services really enable the physician to successfully navigate that PA process |
| HCPs that we have reached with our messaging are responding favorably to the differentiated mechanism of action and clinical data profile, adopting IBSRELA, and continuously expanding their use based on the patient responses they are seeing |
| At just three months since launch in November, we are very pleased to see the market responding as we anticipated |
| The fundamentals driving IBSRELA's growth momentum are strong |
| We are excited about IBSRELA's performance, the early days of XPHOZAH, and the strength of our cash position |
| The high level of awareness, interest, and intent to adopt has translated into strong initial product uptake |
| You can expect to see continued steady growth throughout the year |
| What I believe you will hear from the information we have provided today is, we find ourselves in a strong financial position |
| Favorable treatment experiences are driving expanded use, which, in turn, is driving a continuously expanding view of patients who are candidates for IBSRELA therapy |
| We continue to see consistent, persistent growth of IBSRELA across all key performance metrics |
| net product sales revenue in 2023 compared to $15.6 million in 2022 as a result of consistent and persistent growth in all key metrics |
| One small pill twice a day, especially if it's being added to a therapy regimen, the patients are responding really favorably, like, wow, I could take this |
| We're very confident with the approach that we're taking in the business with XPHOZAH, and obviously continue to monitor and participate as much as is practicable in what's trying to be accomplished in DC |
| Statement |
|---|
| In 2022, we reported a net loss of $67.2 million or $0.42 per share for the full year |
| Our net loss for the full year of 2023 was $66.1 million or $0.30 per share, which included $17.9 million of non-cash expenses from share-based compensation, non-cash interest expense related to the sale of future royalties and impairment of a right of lease use asset |
| So, and what we're finding now on the market in front of nephrologists is that they believe that the majority of their patients are unable to achieve or maintain target levels with binder therapy |
| So due to the government segment rebate dynamics, we expect that the growth to net deduction may be slightly unfavorable for XPHOZAH compared to IBSRELA when it's somewhat early, and of course, we haven't really experienced the seasonality yet because it's obviously the first time we've watched and started selling XPHOZAH in the first quarter of the calendar year |
| Susan, anything to add? Susan Rodriguez Yeah, I would just add that it's really important to note that consistently we see approximately 70% of patients, despite treatment with binders, are unable to achieve or maintain the, you know, global guideline target levels within a six-month period |
| Interest is high |
| We had a net loss of approximately $28.8 million or $0.12 per share in the fourth quarter of 2023 compared to net income of $10.7 million or $0.06 per fully diluted share in the same period of 2022 |
| My question is, you know, from our recent discussions with nephrologists over the last few weeks, we're hearing a heavy interest actually in the perceived compliance benefit associated with XPHOZAH for patient subpopulations, actually both with and without adequately controlled serum phosphorous |
| New writers are growing, and use across the existing writer base is persistently growing |
| The net loss for the fourth quarter of 2023 includes $5 million in combined non-cash expenses from share-based compensation and non-cash interest expense related to the sale of future royalty |
Please consider a small donation if you think this website provides you with relevant information